Φορτώνει......
PATH-17. CORRELATION OF COMMERCIALLY-AVAILABLE QUANTITATIVE MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) METHYLATION SCORES AND OVERALL GBM PATIENT SURVIVAL
OBJECTIVE: Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer. One of the most robust clinically-obtained biomarkers available for GBM is MGMT promoter methylation, which predicts improved outcome to standard of care alkylating chemotherapy. MGMT promoter leads to g...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Neuro Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Oxford University Press
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692826/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.708 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|